CSL has 'money burning a hole in our pocket,' but it won't make premium deals

Australian drugmaker CSL has plenty of wherewithal to make some deals, CEO Paul Perreault says, but he's wary of the prices paid by other drugmakers. Big Pharma's penchant for biotech deals has created "a bit of a bubble," in Perreault's view. "Just because I have money burning a hole in our pocket doesn't mean I have to go out and buy something," he told the Financial Times. "It is really hard to do something that really adds value." Report (sub. req.)

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.